Benzimidazol-1,2-yl Amides for Selective Kv7.2/7.3 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing Kv7 channel modulators, such as retigabine, have complex and often concentration-dependent effects on neuronal Kv7 channels, leading to unclear modes of interaction and potential untoward side effects, necessitating the development of compounds that are more potent and specific for the Kv7.2/7.3 heteromultimer over the Kv7.4 homomultimer to reduce side effects.
Innovation Solution
Development of benzoimidazol benzimidazol-1,2-yl amides that act as potent activators of Kv7.2/7.3 heteromultimers, offering reduced side effects by specifically targeting these channels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Kv7 channel modulators such as retigabine are used, then channel activation is achieved, but complex concentration-dependent effects and untoward side effects occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (benzoimidazol-1,2-yl amide core with particular substituents) that confer selective affinity for Kv7.2/7.3 heteromultimers. This structural specificity ensures the compound acts locally on the target channel subtype, producing activation effects without the complex concentration-dependent behavior and side effects associated with non-selective modulators like retigabine.
2Adaptability or versatility
If non-specific Kv7 channel activators are used, then broad channel activation occurs, but specificity for Kv7.2/7.3 heteromultimer is reduced
Solution Approach 1:
The compounds are designed with specific local structural characteristics (benzoimidazol-1,2-yl amide scaffold with defined substituents R1-R6) that create high affinity and selectivity for Kv7.2/7.3 heteromultimers. This structural precision enables the compound to distinguish between different Kv7 channel subtypes, achieving high measurement precision in target recognition while maintaining controlled activation breadth.
Solution Approach 2:
The patent employs parameter changes by systematically varying substituent parameters (R1-R6 groups) on the core benzoimidazol-1,2-yl amide structure to optimize binding affinity and selectivity for Kv7.2/7.3 heteromultimers. By adjusting these chemical parameters, the compounds achieve enhanced specificity for the target channel subtype while maintaining pharmacological activity.
Data Source
AI summary
Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.